Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 15
- Registration Number
- NCT04713761
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
- Conditions
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 61
- Registration Number
- NCT04653480
- Locations
- 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Wei Ren
- Target Recruit Count
- 32
- Registration Number
- NCT04644250
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 88
- Registration Number
- NCT04640545
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 600
- Registration Number
- NCT04627012
- Locations
- 🇨🇳
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04627363
Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Sun Yan
- Target Recruit Count
- 81
- Registration Number
- NCT04624308
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04603040
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, China
🇨🇳Affiliated Hospital of Qingdao University, Qingdao, China
Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Tao Zhang
- Target Recruit Count
- 54
- Registration Number
- NCT04563975
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04553939
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.